VIA
NTLA icon

Vident Investment Advisory’s Intellia Therapeutics NTLA Stock Holding History

Vident Investment Advisory’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,664
Closed -$516K – 693
2023
Q2 		$516K Buy
12,664
+1,362
+12% +$55.2K 0.02% 686
2023
Q1 		$421K Buy
11,302
+4,696
+71% +$184K 0.01% 839
2022
Q4 		$230K Buy
+6,606
New +$314K 0.01% 980
2021
Q4 		– Sell
-1,628
Closed -$219K – 1227
2021
Q3 		$219K Sell
1,628
-898
-36% -$136K 0.01% 1067
2021
Q2 		$409K Buy
+2,526
New +$197K 0.01% 885

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vident Investment Advisory's NTLA Position: Q3 2023 in Review

Vident Investment Advisory sold out of Intellia Therapeutics (NTLA) in Q3 2023, closing a stake of 12,664 shares — an estimated $516K sold.

Vident Investment Advisory first reported a position in NTLA in Q2 2021 and held it in 5 quarters. The position peaked at $516K in Q2 2023. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

  • Vident Investment Advisory reported no remaining Intellia Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 12,664 Intellia Therapeutics shares in Q3 2023, an estimated $516K.
  • Vident Investment Advisory first reported a position in Intellia Therapeutics in Q2 2021 and held it in 5 quarters.
  • Vident Investment Advisory's Intellia Therapeutics position peaked at $516K in Q2 2023.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.